WO1991001745A1 - Growth factors containing vitamin a or other retinoids and uses thereof - Google Patents
Growth factors containing vitamin a or other retinoids and uses thereof Download PDFInfo
- Publication number
- WO1991001745A1 WO1991001745A1 PCT/US1990/004198 US9004198W WO9101745A1 WO 1991001745 A1 WO1991001745 A1 WO 1991001745A1 US 9004198 W US9004198 W US 9004198W WO 9101745 A1 WO9101745 A1 WO 9101745A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- complex
- retinoid
- growth
- retinol
- cells
- Prior art date
Links
- 239000003102 growth factor Substances 0.000 title claims abstract description 35
- 229940045997 vitamin a Drugs 0.000 title description 6
- 150000004492 retinoid derivatives Chemical class 0.000 claims abstract description 60
- 210000003719 b-lymphocyte Anatomy 0.000 claims abstract description 51
- 102000029752 retinol binding Human genes 0.000 claims abstract description 50
- 108091000053 retinol binding Proteins 0.000 claims abstract description 50
- 230000012010 growth Effects 0.000 claims abstract description 48
- 108010071690 Prealbumin Proteins 0.000 claims abstract description 44
- 102000007584 Prealbumin Human genes 0.000 claims abstract description 44
- 238000000034 method Methods 0.000 claims abstract description 31
- 239000001963 growth medium Substances 0.000 claims abstract description 17
- 210000004881 tumor cell Anatomy 0.000 claims abstract description 16
- 239000002609 medium Substances 0.000 claims abstract description 14
- 230000010261 cell growth Effects 0.000 claims abstract description 12
- 230000002708 enhancing effect Effects 0.000 claims abstract description 12
- 210000004102 animal cell Anatomy 0.000 claims abstract description 11
- 239000000203 mixture Substances 0.000 claims abstract description 11
- 235000015097 nutrients Nutrition 0.000 claims abstract description 6
- 238000012258 culturing Methods 0.000 claims abstract description 5
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims description 67
- 102000004169 proteins and genes Human genes 0.000 claims description 41
- 108090000623 proteins and genes Proteins 0.000 claims description 41
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 claims description 38
- 235000019169 all-trans-retinol Nutrition 0.000 claims description 20
- 239000011717 all-trans-retinol Substances 0.000 claims description 20
- 229940100609 all-trans-retinol Drugs 0.000 claims description 20
- 101000772194 Homo sapiens Transthyretin Proteins 0.000 claims description 9
- NCYCYZXNIZJOKI-OVSJKPMPSA-N Retinaldehyde Chemical compound O=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-OVSJKPMPSA-N 0.000 claims description 7
- 230000004071 biological effect Effects 0.000 claims description 6
- 210000004962 mammalian cell Anatomy 0.000 claims description 6
- NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Natural products O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 claims description 6
- 230000002860 competitive effect Effects 0.000 claims description 4
- 239000003112 inhibitor Substances 0.000 claims description 4
- 101000772196 Bos taurus Transthyretin Proteins 0.000 claims description 3
- 239000003104 tissue culture media Substances 0.000 claims description 3
- NCYCYZXNIZJOKI-HWCYFHEPSA-N 13-cis-retinal Chemical compound O=C/C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-HWCYFHEPSA-N 0.000 claims description 2
- FPIPGXGPPPQFEQ-HWCYFHEPSA-N 13-cis-retinol Chemical compound OC/C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-HWCYFHEPSA-N 0.000 claims description 2
- FPIPGXGPPPQFEQ-DPZDGVIMSA-N dihydroretinol Natural products CC(=CCO)C=CC=C(C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-DPZDGVIMSA-N 0.000 claims description 2
- 241000124008 Mammalia Species 0.000 claims 1
- 210000004027 cell Anatomy 0.000 abstract description 61
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 39
- 235000018102 proteins Nutrition 0.000 description 39
- 150000002632 lipids Chemical class 0.000 description 38
- 230000000694 effects Effects 0.000 description 31
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 22
- 210000002966 serum Anatomy 0.000 description 22
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 21
- 239000012679 serum free medium Substances 0.000 description 19
- 229960003471 retinol Drugs 0.000 description 16
- 239000011607 retinol Substances 0.000 description 16
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 15
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 14
- 230000003305 autocrine Effects 0.000 description 12
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Natural products O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 11
- 238000003556 assay Methods 0.000 description 11
- 235000020944 retinol Nutrition 0.000 description 11
- 239000000872 buffer Substances 0.000 description 10
- 229960001701 chloroform Drugs 0.000 description 10
- 239000000463 material Substances 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 9
- 238000002523 gelfiltration Methods 0.000 description 8
- 238000004128 high performance liquid chromatography Methods 0.000 description 8
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 8
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 7
- 239000002953 phosphate buffered saline Substances 0.000 description 7
- 229930002330 retinoic acid Natural products 0.000 description 7
- 239000011780 sodium chloride Substances 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 239000012980 RPMI-1640 medium Substances 0.000 description 6
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 239000012894 fetal calf serum Substances 0.000 description 6
- 239000000499 gel Substances 0.000 description 6
- 238000004255 ion exchange chromatography Methods 0.000 description 6
- 230000004936 stimulating effect Effects 0.000 description 6
- 229940104230 thymidine Drugs 0.000 description 6
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 5
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 5
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 5
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 5
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 5
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 5
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 5
- 229940095259 butylated hydroxytoluene Drugs 0.000 description 5
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 5
- 239000003636 conditioned culture medium Substances 0.000 description 5
- 238000005342 ion exchange Methods 0.000 description 5
- 239000012071 phase Substances 0.000 description 5
- 238000004007 reversed phase HPLC Methods 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- 229960001727 tretinoin Drugs 0.000 description 5
- 102000003390 tumor necrosis factor Human genes 0.000 description 5
- 235000019155 vitamin A Nutrition 0.000 description 5
- 239000011719 vitamin A Substances 0.000 description 5
- 102000004506 Blood Proteins Human genes 0.000 description 4
- 108010017384 Blood Proteins Proteins 0.000 description 4
- XUIIKFGFIJCVMT-GFCCVEGCSA-N D-thyroxine Chemical compound IC1=CC(C[C@@H](N)C(O)=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-GFCCVEGCSA-N 0.000 description 4
- 102000004877 Insulin Human genes 0.000 description 4
- 108090001061 Insulin Proteins 0.000 description 4
- 230000000975 bioactive effect Effects 0.000 description 4
- 229960004132 diethyl ether Drugs 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 235000004626 essential fatty acids Nutrition 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 229940125396 insulin Drugs 0.000 description 4
- 238000001155 isoelectric focusing Methods 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 229940034208 thyroxine Drugs 0.000 description 4
- XUIIKFGFIJCVMT-UHFFFAOYSA-N thyroxine-binding globulin Natural products IC1=CC(CC([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-UHFFFAOYSA-N 0.000 description 4
- 231100000331 toxic Toxicity 0.000 description 4
- 230000002588 toxic effect Effects 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 208000002109 Argyria Diseases 0.000 description 3
- GUBGYTABKSRVRQ-WFVLMXAXSA-N DEAE-cellulose Chemical compound OC1C(O)C(O)C(CO)O[C@H]1O[C@@H]1C(CO)OC(O)C(O)C1O GUBGYTABKSRVRQ-WFVLMXAXSA-N 0.000 description 3
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 102000004338 Transferrin Human genes 0.000 description 3
- 108090000901 Transferrin Proteins 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 238000012870 ammonium sulfate precipitation Methods 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 238000010348 incorporation Methods 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 3
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 3
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 3
- 239000012581 transferrin Substances 0.000 description 3
- WFIYPADYPQQLNN-UHFFFAOYSA-N 2-[2-(4-bromopyrazol-1-yl)ethyl]isoindole-1,3-dione Chemical compound C1=C(Br)C=NN1CCN1C(=O)C2=CC=CC=C2C1=O WFIYPADYPQQLNN-UHFFFAOYSA-N 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 2
- 108010088751 Albumins Proteins 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 108010038061 Chymotrypsinogen Proteins 0.000 description 2
- 230000006820 DNA synthesis Effects 0.000 description 2
- 229920001917 Ficoll Polymers 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 229920002684 Sepharose Polymers 0.000 description 2
- 241000191967 Staphylococcus aureus Species 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 150000007513 acids Chemical group 0.000 description 2
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 2
- 150000004347 all-trans-retinol derivatives Chemical class 0.000 description 2
- 238000000376 autoradiography Methods 0.000 description 2
- 239000007640 basal medium Substances 0.000 description 2
- 238000004166 bioassay Methods 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 239000000469 ethanolic extract Substances 0.000 description 2
- 239000012259 ether extract Substances 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 238000001641 gel filtration chromatography Methods 0.000 description 2
- 210000005260 human cell Anatomy 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 239000012299 nitrogen atmosphere Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 238000000638 solvent extraction Methods 0.000 description 2
- 238000000527 sonication Methods 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 150000002266 vitamin A derivatives Chemical class 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 102100030497 Cytochrome c Human genes 0.000 description 1
- 108010075031 Cytochromes c Proteins 0.000 description 1
- 108010092160 Dactinomycin Proteins 0.000 description 1
- 101000993347 Gallus gallus Ciliary neurotrophic factor Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 101000872147 Homo sapiens Biogenesis of lysosome-related organelles complex 1 subunit 6 Proteins 0.000 description 1
- 101000693011 Homo sapiens Pancreatic alpha-amylase Proteins 0.000 description 1
- 102000000589 Interleukin-1 Human genes 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- 102000008192 Lactoglobulins Human genes 0.000 description 1
- 108010060630 Lactoglobulins Proteins 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 206010028470 Mycoplasma infections Diseases 0.000 description 1
- 108010058846 Ovalbumin Proteins 0.000 description 1
- 108020002230 Pancreatic Ribonuclease Proteins 0.000 description 1
- 102000005891 Pancreatic ribonuclease Human genes 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 101710097927 Retinal-binding protein Proteins 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- SHGAZHPCJJPHSC-NWVFGJFESA-N Tretinoin Chemical compound OC(=O)/C=C(\C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-NWVFGJFESA-N 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000005571 anion exchange chromatography Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000012888 bovine serum Substances 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000010001 cellular homeostasis Effects 0.000 description 1
- 150000001793 charged compounds Chemical class 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000000139 costimulatory effect Effects 0.000 description 1
- 239000012531 culture fluid Substances 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 229960000640 dactinomycin Drugs 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000015961 delipidation Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 238000002481 ethanol extraction Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 208000018212 fibroblastic neoplasm Diseases 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000003365 glass fiber Substances 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 102000056984 human BLOC1S6 Human genes 0.000 description 1
- 230000005965 immune activity Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 229940057952 methanol Drugs 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 229940092253 ovalbumin Drugs 0.000 description 1
- 210000004976 peripheral blood cell Anatomy 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229940093429 polyethylene glycol 6000 Drugs 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000009696 proliferative response Effects 0.000 description 1
- 238000002731 protein assay Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 102000024458 retinal binding proteins Human genes 0.000 description 1
- 125000000946 retinyl group Chemical group [H]C([*])([H])/C([H])=C(C([H])([H])[H])/C([H])=C([H])/C([H])=C(C([H])([H])[H])/C([H])=C([H])/C1=C(C([H])([H])[H])C([H])([H])C([H])([H])C([H])([H])C1(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 239000011833 salt mixture Substances 0.000 description 1
- 238000007127 saponification reaction Methods 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000007447 staining method Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/07—Retinol compounds, e.g. vitamin A
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/76—Albumins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0635—B lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/38—Vitamins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/70—Undefined extracts
- C12N2500/80—Undefined extracts from animals
- C12N2500/84—Undefined extracts from animals from mammals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/30—Hormones
- C12N2501/38—Hormones with nuclear receptors
- C12N2501/385—Hormones with nuclear receptors of the family of the retinoic acid recptor, e.g. RAR, RXR; Peroxisome proliferator-activated receptor [PPAR]
Definitions
- Autocrine growth factors - factors produced by the target cells themselves - were first demonstrated for certain fibroblastic tumors in 1978 (1) . Since then, autocrine growth factors have been described for sever ⁇ al othGr tumors (2-5) , and it has been recognized that normal cell such as activated T cells produce autocrine growth factors (6) .
- lymphoblastoid cell lines created by transforma- ti n with Epstein-Barr virus (EBV) , make autocrine growth factors.
- Buck et al. (10%) described experiments to purify and characterize an autocrine growth factor produced by an EBV-transformed cell line. It was believed that the material was purified to apparent homogeneity and had no interleukin 1 activity.
- the present inventors determined that the sequence of the protein was highly homologous to human prealbumin and that in fact bovine prealbumin had been isolated from fetal calf serum. It was also noted that the purified protein was not nearly as effective as a crude preparation, indicating the existence of a cofactor which was lost in later purification steps.
- This cofactor was found to be a lipid, and through chromatography and other analysis it has been determined that the lipid is comprised of all-trans- retinol, commonly known as vitamin A. It has also been recognized that a second protein, retinol-binding protein, is contained in the growth factor.
- the present invention concerns the combination of prealbumin, retinol-binding protein and all-trans-retinol or other retinoids.
- This invention provides a complex consisting essentially of prealbumin, retinol-binding protein, and a retinoid which binds to retinol-binding protein, wherein the concentration of retinoid in the complex is
- This invention also provides a complex consisting essentially of retinol-binding protein and a retinoid which binds to retinol-binding protein, wherein the concentration of retinoid in the complex is from about
- This invention also provides a composition for enhancing the growth of human B cells in culture which comprises an amount of the complex of this invention effective to enhance the growth of human B cells and a nutrient medium.
- This invention further provides a method of making the complex of this invention which comprises contacting retinol-binding protein with a retinoid which binds to retinol-binding protein under conditions such that the protein and the retinoid form an intermediate complex, and contacting the intermediate complex with prealbumin under conditions that the intermediate complex and the prealbumin form a complex, wherein the concentration of retinoid in the complex is from about 2x10 M to about 10 M and the concentration of prealbumin and retinol- binding protein is sufficient to maintain the retinoid
- This invention further provides a method of enhancing growth of human B cells in culture comprising growing the cells in culture in a growth medium containing a concentration of the complex of the subject invention effective to enhance growth of the human B cells.
- This invention also provides a method of enhancing growth of mammalian cells in culture which comprises adding the complex of the subject invention to a synthetic tissue culture medium so as to obtain in the medium a concentration of the complex effective to enhance growth of the mammalian cells.
- This invention also provides a synthetic growth medium for culturing animal cells comprising the complex of this invention at a concentration effective to enhance cell growth.
- this invention provides a method of preventing the growth of human tumor cells containing growth factor which comprises removing the growth factor from the human tumor cells.
- Figure 1 shows comparison between the N-terminal amino acid sequence of "aBGF” protein and human prealbumin.
- the first 28 N-terminal acids of purified aBGF protein were determined in an automated Edman degradation instrument. They are identical with human prealbumin except for the portions indicated.
- Figure 2 shows autocrine growth factor activity after ion exchange and gel filtration chromatography.
- aBGF Purification of aBGF followed the procedure given in reference 14 and outlined in the section of this application entitled "Materials and Methods". Briefly, the EBV-transformed cell line 5/2 was incubated 24 h at 6 x 10 cells/ml in serum-free medium. Proteins were concentrated from the conditioned medium by ammonium sulfate precipitation at 80% saturation, and separated by ion exchange chromatography on DE 52. Active fractions were pooled and further separated by gel filtration on AcA 54 (10) . For activity assays, 5/2 target cells, washed three times with serum-free medium, were incubated at 2 x 10 /ml for 72 hr in serum-free medium containing growth factor as indi- cated. Cells were labelled for the last 16 h with H- thymidine.
- ⁇ c.p.m. expresses the differential between experimen ⁇ tal values and the background response of 196 + 37 CPM.
- Figure 3 shows that delipidated aBGF protein synergizes with aBGF lipid to enhance the growth of human lymphoblastoid cells.
- Figure 4 shows that autocrine B cell growth factor components are effective on normal human B cells at low cell densities.
- B cells were prepared from normal human spleens by Ficoll gradient centrifugation followed by treatment with OKT 4 and OKT 8 antibodies plus rabbit complement and passage through a Sephadex G-10 column. Recovered cells contained more than 90% slg cells.
- SAC-activated B cells (500,000 cells/ml, 0.03% SAC in serum-free medium incubated for 48 hr) were washed three times and seeded at different cell concentrations in medium alone, medium containing human prealbumin, and human prealbumin plus active lipid or factor obtained by ion exchange chromatography. The cells were incubated further for 72 hours in serum-free medium and pulsed for the last 16 hours with 3 H- thymidine. The data points represent means of
- ⁇ c.p.m. symbolizes experimental minus background counts of the scintillation counter (114 + 16 c.p.m.).
- Figv -e ⁇ shows a comparison of bioactivity between all- trans-retinol, all-trans-retinal and all-trans-retinoic acid. . Bioactivity was tested on lymphoblastoid cells.
- Figure 6 shows reversed phase C. & HPLC column chromatography. Bioactivity was tested on lymphoblastoid cells.
- Figure 7A shows the mass spectometry of Fraction 34 from Figure 6. Fraction 34 was analyzed using a direct insetion probe in a V670-250 double focusing mass spectrometer.
- Figure 7B shows the mass spectometry from the library reference for all-trans-retinol.
- Figure 8 shows evidence for biosynthesis of prealbumin by incorporation of 35S cysteine and 35S methionine into the prealbumin and retinol-binding protein peptide.
- This invention provides a complex consisting essentially of prealbumin, retinol-binding protein, and a retinoid which binds to retinol-binding protein, wherein the concentration of retinoid in the complex is from about 2x10 -_.M to about 10—10M and the concentration of prealbumin and retinol-binding protein is sufficient to maintain the retinoid concentration from about 2x10 —5M to about 10—10M.
- the growth factor has a narrow physiological range for activity since the individual, uncomplexed components may be toxic to cells.
- the prealbumin is ideally at a range from about 50 to about 200 -g/ml.
- the retinol- binding protein is ideally at a range from about 20 to aobut 40 ⁇ g/ml.
- the optimum ratio is equimolar amounts of each component.
- retinoids- includes, but is not limited to, all-trans-retinol, iso ers of vitamin A such as the cis-trans isomers, derivatives of vitamin A such as retinol esters as well as the family of retinal isomers and derivatives and the family of retinoic acid, isomer and derivatives. Specific examples include all-trans-retinol, all-trans-retinal, 13-cis-retinol and 13-cis-retinal.
- the prealbumin in the complex may be characterized as mammalian.
- the mammalian prealbumin may be characterized as bovine or human.
- This invention also provides a complex consisting essentially of retinol-binding protein and a retinoid which binds to retinol-binding protein, wherein the concentration of retinoid in the complex is from about
- the present invention also provides a composition for enhancing the growth of human B cells in culture which comprises an amount of the complex of this invention effective to enhance i_he growth of human B cells and a nutrient medium.
- the nutrient medium may be any of the standard mediums which meets the minimum biochemical requirement to sustain growth of cells.
- One such example includes but is not limited to a basal amino acid/salt mixture such as RPMI 1640 supplemented with insulin transferin- scleinium and essential fatty acids bound to albumin. These mediums are well known in the art.
- This invention also provides a composition for enhancing the growth of human B cells in culture which comprises an amount of the complex of the subject invention effective to enhance the growth of human B cells and a nutrient medium.
- This invention further provides a method of making the complex of this invention which comprises contacting retinol-binding protein with a retinoid which binds to retinol-binding protein under conditions such that the protein and the retinoid form an intermediate complex, and contacting the intermediate complex with prealbumin under conditions that the intermediate complex and the prealbumin form a complex, wherein the concentration of retinoid in the complex is from about 2x10-5M to about
- prealbumin and retinol- binding protein is sufficient to maintain the retinoid ccoonncceennttrraattiioonn ffrroomm aabbooiut 2x10 -5M to about 10-10M, and recovering the complex.
- the invention also provides a method of enhancing growth of human B cells in culture which comprises growing human B cells in a growth medium containing a concentration of the growth factor described hereinabove effective to c_..__ant-e growth of human B cells.
- the growth medium is a synthetic growth medium.
- synthetic growth media include, but are not limited to, a basal medium known in the art (e.g. RPMI 1640, insulin, transferrin and essential fatty acids) supplemented with the complex of the subject invention at a concentration effective to enhance the growth of cells.
- the individual components of the growth factor may be toxic if not contained within the complex.
- the growth of human B cells will not be enhanced if the individual components of the growth factor are contacted with the B cells without first forming a complex. Therefore, the components of the growth factor, specifically the prealbumin, retinol-binding protein and retinoid, should be preassembled and complexed prior to contact with the B cells.
- This invention also provides a method of enhancing growth of animal cells in culture which comprises adding to an synthetic tissue culture medium the complex of the subject invention so as to obtain in the maxim a concentration of complex effective to enhance growth of the animal cells.
- the cells may further be characterized as mammalian.
- This invention also provides a synthetic growth medium for culturing animal cells comprising the aforementioned complex at a concentration effective to enhance cell growth.
- synthetic growth medium include, but are not limited to, a basal medium known in the art (e.g. RPMI 1640, insulin, transferrin and essential fatty acids) supplemented with the complex of the subject invention at a concentration effective-to enhance the growth of cells.
- the cells may be characterized as mammalian cells. In a further embodiment, the cells may be characterized as human B cells.
- the invention also provides a method of preventing the growth of human tumor cells containing growth factor which comprises removing the growth factor from the human tumor cells.
- the invention further provides a method of preventing the growth of human tumor cells containing retinoid which comprises removing the retinoid from the human tumor cells.
- the retinoid is all-ttans-retinol.
- the invention also provides a method of preventing the growth of human tumor cells containing a complex of retinoid ahd retinol-binding protein which comprises substituting for the retinoid in the complex a competitive inhibitor which lacks the biological activity of the retinoid and which binds to retinol- binding protein.
- the retinoid is all-trans-retinol.
- this invention provides a method of preventing the growth of human tumor cell containing a retinoid which comprises substituting for the retinoid a competitive inhibitor which lacks the biological activity of the retinoid.
- the retinoid is all- trans-retinol.
- Retinoids All-trans-retinol, all-trans-retinal and retinoic acid were purchased from commercially- available sources. The retinoids were dissolved at a concentration of 3 x 10 M in methanol/chloroform (3:1 v/v) with 10 ⁇ 4 M butylated hydroxy toluene (BHT) added and stored in the dark at -20*C in a nitrogen atmosphere. Immediately before a bioassay, the str . solutions were diluted in serum-free medium.
- the human EBV-transformed B LCL 5/2 was established from the peripheral blood cells of a healthy donor according to a known method (10) .
- the cell line was grown in RPMI 1640 supplemented with 8% fetal calf serum, L-glutamine (2 mM) , nonessential a ino acids (10 mM) , and antibiotics.
- the cells were tested regularly for mycoplasma infections and were consistently negative.
- B cells were prepared from normal human spleens by Ficoll gradient centrifugation followed by OKT4 and • 0KT8 treatment plus rabbit complement and passage through a Sephadex G-10 column. Recovered cells contained more than 90% slg + cells.
- the assay system was a modification of the assay developed by Blazar et al. (7) and Gordon et al. (8). Lymphoblastoid cells grown for 18 to 24 hr in serum-free medium at a cell density of 4 x 10 cells/ml or B cells activated by SAC- or anti- ⁇ for 48 h were washed four times in RPMI 1640/0.1% fetal calf serum (FCS) . The cells (2 x 10 /ml) were then plated in a final volume of 200 ⁇ l/well of serum-free medium in 96-well microtiter plates and grown for 72 hr in the presence of log. dilutions of putative growth factor.
- Freshly prepared 5/2 cell line-conditioned medium was used as positive control. Fresh serum-free medium was the negative control. After 56 hr of culture the cells were labeled witii 0.4 ⁇ Ci/well of [ H]thymidine (specific activity, 6.7 Ci/mmol) and 16 hr later harvested on glass fiber strips. [ H] Thymidine incorporation was measured in a liquid scintillation counter. Units of autocrine B cell growth factor (aBGF) were determined according to Table 1.
- Fraction 23 corresponds to 200 ⁇ /ml.
- the aBGF activity was determined with the assay for autocrine growth activity described in Materials and
- Lipid separation on a reversed-phase HPLC column The crude lipid mixture was loaded on a semipreparative reversed-phase C.g HPLC column. Lipids were eluted with a linear gradient of water/methanol/chloroform. The gradient started with water/methanol 70:30 (v/v), went in 30' to 100% methanol and in another 30' to methanol/chloroform 50:50 (v/v). The flow rate was 3 ml/min.
- retinol-retinol binding protein complex 40 mg of human prealbumin were covalently bound to 3 ml of CNBr activated sepharose. 50 ml of human plasma were passed through the column. The column was washed with 30 ml of 0.04M Tris HCl (pH 7.4)/0.5M NaCl and eluted with 1 ml fractions of distilled water. Purity was established by SDS-PAGE with silver stain and the optical densities at 280 nm and 340 nm were determined.
- IL 1 activity was assessed in the lymphocyte activation factor assay (11) , which we modified slightly by using 0.5% human serum instead of FCS. Recombinant human IL 1- was used as reference standard.
- TNF activity was measured on TNF-sensitive L(M) cells (12) in 96-well microtiter plates with 1.0 ⁇ g/ml of actinomycin D added. TNF-resistant L(M) cells were used to exclude nonspecific toxicity. The cells were 3 pulsed after 24 hr with 0.4Ci/well of [ H]thym ⁇ dine for TNF activity.
- IL 2 was assayed by using the IL 2-dependent murine cytotoxic T cell line 1 (13) .
- Ammonium sulfate precipitation (NH.J-SO. (1683g) was added to 3 liters of 5/2 cell line-conditioned medium to achieve 80% saturation. After gentle stirring overnight at 4*C, the precipitate was spun down (10,000 x G. 30 min), dissolved in 0.05 M Tris-HCl, pH 7.8, in a final volume of 135 ml, and subsequently dialyzed against 50 volumes of 0.5 M Tris-HCl buffer, pH 7.8 for hr with five changes of the dialyzing buffer.
- Anion exchange chromatography (DEAE-cellulose) .
- the dialyzed concentrate was loaded on 250-ml column of DEAE-cellulose, equilibrated with 0.05 M Tris-HCl, pH 7.8.
- Bound proteins were eluted with a stepwise gradient of Tris-buffered NaCl: 0.075 M NaCl (150 ml), 0.125 M NaCl (250 ml), 0.175 M NaCl (250 ml), and 0.300 m NaCl (250 ml).
- Fraction size was 25 ml.
- Fractions containing growth factors were pooled and concentrated by dialyzing against phosphate-buffered saline (PBS), pH .7.2, containing polyethyleneglycol (relative molecular mass (M ) 6000) (polyethyleneglycol 6000; 50% w/v). Gel filtration. The concentration DEAE-cellulose preparation (18 ml) was applied to an AcA 54 Ultrogel column (2.6 x 90 cm), equilibrated with PBS. The flow rate was adjusted to 38 ml/hr and 7.5-ml fractions were collected. The column had been calibrated with .w. markers: bovine serum albumin (M p 68,000), chymotrypsinogen (M 25,700), and ribonuclease A (M 14,300), all co merically obtained.
- PBS phosphate-buffered saline
- M 6000 relative molecular mass
- Reversed-phase high performance liquid chromatography (RP-HPLC) .
- the separation was performed on a C.- column.
- Buffer A was 100 mM CH 3 COONH 4 pH 4.0 and buffer B was buffer A in 50% 1-propanol.
- the pool containing growth activity obtained from gel filtration was acidified with acetic acid to pH 4.0 and loaded onto the C. choir column without regard to sample volume.
- the column was washed with buffer A (20 min) , and bound proteins were eluted by using a steep gradient of 0 to 40% buffer B within the first 20 min and a 40 to 100% gradient of buffer B in 120 min.
- the percentage of buffer A was inversely proportional to buffer B.
- the flow rate was adjusted to 1 ml/min and 3-ml fractions were collected.
- Isoelectric focusing (IEF) .
- aBGF Isoelectric focusing
- Protein assay The protein content of samples was measured by absorption at 280 nm. For protein concentrations of ⁇ 2 ⁇ g/ml, samples were subjected to NaDodSO./PAGE; the protein bands were visualized by the silver-staining technique, and the protein concentration was estimated by comparison with a serial dilution of known amounts of proteins.
- Lymphoblastoid cells were labelled with 35S cysteine and 35S methionine. The supernatant was precipitated with ammonium sulfate. The prealbumin/retinol-binding protein complex was separated with an affinity column. The proteins were separated by a SDS PAGE gel with silver staining. Results
- B cell-produced lipids also may participate in B cell homeostasis and that bioactive lipid molecules may use serum proteins as carriers.
- B cell-derived B cell growth factor 10
- a lipid-protein complex with novel biological properties has been found. This complex occurs in serium and in the culture fluids of EBV- transformed human B lymphocytes and of activated normal human B cells.
- the protein moieties of the complex are prealbumin and retinol-binding protein.
- the lipid moiety of the complex comprises all-trans-retinol, commonly known as vitamin A, or derivatives of vitamin A.
- aBGF autocrine B cell growth factor
- Washed 5/2 cells (1,500/well) were incubated for 72 h in serum-free medium. DNA synthesis was assessed as described. The experiment was done in triplicate.
- Protein and lipid concentrations correspond to 3% serum.
- ⁇ e full physiologica functions of prealbumin are unknown, except fo evidence that it acts as a carrier for thyroxine and o vitamin A via retinal-binding protein.
- the subunit are so arranged as to form a central channel containin two binding sites for thyroxine (12-14) .
- Serum lipids were 'isolated from human serum by solvent extraction with diethylether/ethanol or chlor form/methanol/water mixtures.
- Delipidated proteihs were the residue after ether/ethanol extraction.
- the growth stimulatory effects of lipids and delipidated proteins for EBV-transformed cells were tested either alone or in combination. The results of
- Washed 5/2 target cells were cultured in triplicate at
- Results are recorded as the average of triplicate cultures. The standard deviations were less than 20%.
- ⁇ c.p.m. expresses the differential between total c.p.m. and the background response (156 + 28) .
- ⁇ Microscopic inspection showed all cells to be dead. thymidine uptake by either compound alone, but when mixed, a synergistic effect occurred which nearly matched the growth stimulation potential of whole serum.
- Figure 5 shows a comparison of bioactivity between all- trans-retinol, all-trans-retinal and all-trans-retinoic acid. Bioactivity was tested on lymphoblastoid cells.
- the culture medium may also be synthetic, comprising a basal Inedium known in the art (e.g. RPMI 1640, insulin, transferrin and essential fatty acids) supplemented with the complex at a concentration effective to enhance the growth of cells.
- a basal Inedium known in the art e.g. RPMI 1640, insulin, transferrin and essential fatty acids
- Crude lipid activity was resistant to saponification with 4M potassium hydroxide for two hours at 37*C but was not stable over prolonged periods of time in aque ⁇ ous solution at 4*C and was destroyed by ultraviolet light.
- the bioactivity decayed within hours at room temperature but decay could be slowed by the addition of the antioxidant butylated hydroxy toluene (BHT) and by storage of the sample in the dark at -80"C in a nitrogen atmosphere.
- BHT antioxidant butylated hydroxy toluene
- the lipid mixture was chromatographed on a reversed phase C-- HPLC column (Fig. 6) with a linear water/methanol/chloroform gradient and 89% of total bioactivity had been eluted at minute 34.
- Washed B cell blasts were incubated for 72 h in serum-free medium. DNA synthesis was assessed as described. The experiment was done in triplicate.
- retinol binding protein RBP
- PA prealbumin
- th RBP-retinol complex When assayed in cultures of lymphoblastoid cells, th RBP-retinol complex showed growth-enhancing activit similar in magnitude to activities of crude seru lipids and of commercially available retinol.
- th RBP-retinol complex was extracted wit methanol/chloroform and the extract subjected to HPL on a C.g column, a single activity peak emerged i fraction 34, the same fraction where authentic all trans-retinol is eluted.
- activated human B cell produce retinol-bining protein and prealbumin an release into the medium ( Figure 8) .
- Dose-response curves establish that all-trans-retinol, tested in serum-free medium in the presence of RBP/PA, is optimally active at a concentration of 2 x 10 " to x 10 M, a range corresponding to the physiologica concentration in serum (10 ⁇ M retinol) .
- a concentrations above 8 retinol is toxic to human cells in serum-free, as well as in 7% serum supple ented medium.
- All-trans-retinal is comparable in bioactivity at a range of 10 —7 to 5 x 10-7 molar, but at 2 x lo " M displays toxicity.
- Retinoic acid commonly--, assumed to be the most active retinol derivative in cell culture, has marginal bioactivity on
- B cells at 10—5 (15 to 25% growth-enhancing capacity as compared to retinol) and is toxic at higher doses.
- concentrations of 4 x 10 —6 M to 6 x 10—8 M there is a noticeable suppression of thymidine incorporation.
- Retinoic acid has not been found in fresh serum at concentrations above 10 —8 M.
Abstract
This invention provides a complex consisting essentially of prealbumin, retinol-binding protein, and a retinoid which binds to retinol-binding protein, wherein the concentration of retinoid in the complex is from about 2x10-5M to about 10-10M and the concentration of prealbumin and retinol-binding protein is sufficient to maintain the retinoid concentration from about 2x10-5M to about 10-10M. This invention also provides a composition for enhancing the growth of human B cells in culture which comprises an amount of the complex of this invention effective to enhance the growth of human B cells and a nutrient medium. This invention further provides a method of enhancing growth of human B cells in culture comprising growing the cells in culture in a growth medium containing a concentration of the complex effective to enhance growth of the cells. This invention also provides a synthetic growth medium for culturing animal cells comprising the complex of this invention at a concentration effective to enhance cell growth. This invention also provides a method of preventing the growth of human tumor cells containing growth factor which comprises removing the growth factor from the human tumor cells.
Description
GROWTH FACTORS CONTAINING VITAMIN A OR OTHER RETINOIDS AND USES THEREOP
This application is a continuation-in-part of U.S.
Serial No. 206,569, filed June 14, 1988, the contents of which are hereby incorporated by reference into the present application.
This invention was made with government support under Grant Number IM-480 from the American Cancer Society. Accordingly, the U.S. Government has certain rights in the invention.
Background of the Invention
Throughout this application, various publications are referenced by arabic numerals within parentheses. Full citation for these publications may be found at the end of the specification immediately preceding the claims. The disclosures of those publications in their entire- ties are hereby incorporated by reference into this application in order to more fully describe the state of the art as known to those skilled therein as of the date of the invention described and claimed.
Autocrine growth factors - factors produced by the target cells themselves - were first demonstrated for certain fibroblastic tumors in 1978 (1) . Since then, autocrine growth factors have been described for sever¬ al othGr tumors (2-5) , and it has been recognized that normal cell such as activated T cells produce autocrine growth factors (6) .
Blazer et al. (7) and Gordon et al. (8) reported that lymphoblastoid cell lines, (LCL) created by transforma-
ti n with Epstein-Barr virus (EBV) , make autocrine growth factors. The factors produced by one LCL stimu¬ late growth of other LCL as well as of normal tonsillar B lymphocytes (9) .
Buck et al. (10) described experiments to purify and characterize an autocrine growth factor produced by an EBV-transformed cell line. It was believed that the material was purified to apparent homogeneity and had no interleukin 1 activity.
Upon further study, the present inventors determined that the sequence of the protein was highly homologous to human prealbumin and that in fact bovine prealbumin had been isolated from fetal calf serum. It was also noted that the purified protein was not nearly as effective as a crude preparation, indicating the existence of a cofactor which was lost in later purification steps.
This cofactor was found to be a lipid, and through chromatography and other analysis it has been determined that the lipid is comprised of all-trans- retinol, commonly known as vitamin A. It has also been recognized that a second protein, retinol-binding protein, is contained in the growth factor.
Whereas neither prealbumin, retinol-binding protein or all-tra-.s-retinol alone showed significant growth- promoting activity, the combination of the three did. This ■purified mixture possesses advantages over crude fetal calf serum because the former does not contain unknown components, is free from viruses and other hormones and growth factors and does not have the problem^of impure antibodies containing calf serum for
propagation of human or animal cell lines in cell culture.
The present invention, therefore, concerns the combination of prealbumin, retinol-binding protein and all-trans-retinol or other retinoids.
Summary of the Invention
This invention provides a complex consisting essentially of prealbumin, retinol-binding protein, and a retinoid which binds to retinol-binding protein, wherein the concentration of retinoid in the complex is
-5 -10 from about 2x10 M to about 10 M and the concentration of prealbumin and retinol-binding protein is sufficient to maintain the retinoid concentration
-5 -10 from about 2x10 M to about 10 M.
This invention also provides a complex consisting essentially of retinol-binding protein and a retinoid which binds to retinol-binding protein, wherein the concentration of retinoid in the complex is from about
2x10-5M to about 10-10M and the concentration of retinol-binding protein is sufficient to maintain the retinoid concentration from about 2xl0~ H to about
10-10M.
This invention also provides a composition for enhancing the growth of human B cells in culture which comprises an amount of the complex of this invention effective to enhance the growth of human B cells and a nutrient medium.
This invention further provides a method of making the complex of this invention which comprises contacting retinol-binding protein with a retinoid which binds to retinol-binding protein under conditions such that the protein and the retinoid form an intermediate complex, and contacting the intermediate complex with prealbumin under conditions that the intermediate complex and the prealbumin form a complex, wherein the concentration of retinoid in the complex is from about 2x10 M to about
10 M and the concentration of prealbumin and retinol- binding protein is sufficient to maintain the retinoid
-5 -10 ccoonncceennttrraattiioonn ffrroomm aabbooiut 2x10 H to about 10 M, and recovering the complex.
This invention further provides a method of enhancing growth of human B cells in culture comprising growing the cells in culture in a growth medium containing a concentration of the complex of the subject invention effective to enhance growth of the human B cells.
This invention also provides a method of enhancing growth of mammalian cells in culture which comprises adding the complex of the subject invention to a synthetic tissue culture medium so as to obtain in the medium a concentration of the complex effective to enhance growth of the mammalian cells.
This invention also provides a synthetic growth medium for culturing animal cells comprising the complex of this invention at a concentration effective to enhance cell growth.
Finally, this invention provides a method of preventing the growth of human tumor cells containing growth factor which comprises removing the growth factor from the human tumor cells.
Brief Description of the Figures
Figure 1 shows comparison between the N-terminal amino acid sequence of "aBGF" protein and human prealbumin.
The first 28 N-terminal acids of purified aBGF protein were determined in an automated Edman degradation instrument. They are identical with human prealbumin except for the portions indicated.
Figure 2 shows autocrine growth factor activity after ion exchange and gel filtration chromatography.
Purification of aBGF followed the procedure given in reference 14 and outlined in the section of this application entitled "Materials and Methods". Briefly, the EBV-transformed cell line 5/2 was incubated 24 h at 6 x 10 cells/ml in serum-free medium. Proteins were concentrated from the conditioned medium by ammonium sulfate precipitation at 80% saturation, and separated by ion exchange chromatography on DE 52. Active fractions were pooled and further separated by gel filtration on AcA 54 (10) . For activity assays, 5/2 target cells, washed three times with serum-free medium, were incubated at 2 x 10 /ml for 72 hr in serum-free medium containing growth factor as indi- cated. Cells were labelled for the last 16 h with H- thymidine.
Δ c.p.m. expresses the differential between experimen¬ tal values and the background response of 196 + 37 CPM.
x - activity after ion exchange chromatography. • * Activity after gel filtration chromatography.
Figure 3 shows that delipidated aBGF protein synergizes with aBGF lipid to enhance the growth of human lymphoblastoid cells.
Pooled growth-factor positive fractions obtained by ion exchange chromatography were delipidated with diethyl- ether/ethanol 1:3 (v/v) (-20'C, overnight). Precipi¬ tated proteins were washed twice in diethylether, dried, redissolved in PBS and dialyzed extensively against PBS.
The combined ether/ethanol extracts were dried on a rotary evaporator. Lipids were dissolved in chloro- form/methanol/water 10:10:1 (v/v). Aliquots of the lipid solution were evaporated to dryness and the re¬ sidual lipids dispersed in serum-free medium by sonication. Dilutions of delipidated protein were mixed with different amounts of lipid. Growth factor activity was assayed as described in Figure 1.
Figure 4 shows that autocrine B cell growth factor components are effective on normal human B cells at low cell densities.
B cells were prepared from normal human spleens by Ficoll gradient centrifugation followed by treatment with OKT 4 and OKT 8 antibodies plus rabbit complement and passage through a Sephadex G-10 column. Recovered cells contained more than 90% slg cells.
SAC-activated B cells (500,000 cells/ml, 0.03% SAC in serum-free medium incubated for 48 hr) were washed three times and seeded at different cell concentrations in medium alone, medium containing human prealbumin, and human prealbumin plus active lipid or factor
obtained by ion exchange chromatography. The cells were incubated further for 72 hours in serum-free medium and pulsed for the last 16 hours with 3H- thymidine. The data points represent means of
5 ttrriipplliiccaa'tes. entries are normalized for 10 cells per culture.
Δ c.p.m. symbolizes experimental minus background counts of the scintillation counter (114 + 16 c.p.m.).
Figv -e Ε shows a comparison of bioactivity between all- trans-retinol, all-trans-retinal and all-trans-retinoic acid. . Bioactivity was tested on lymphoblastoid cells.
Figure 6 shows reversed phase C.& HPLC column chromatography. Bioactivity was tested on lymphoblastoid cells.
Figure 7A shows the mass spectometry of Fraction 34 from Figure 6. Fraction 34 was analyzed using a direct insetion probe in a V670-250 double focusing mass spectrometer.
Figure 7B shows the mass spectometry from the library reference for all-trans-retinol.
Figure 8 shows evidence for biosynthesis of prealbumin by incorporation of 35S cysteine and 35S methionine into the prealbumin and retinol-binding protein peptide.
Detailed Description of the Invention
This invention provides a complex consisting essentially of prealbumin, retinol-binding protein, and a retinoid which binds to retinol-binding protein, wherein the concentration of retinoid in the complex is from about 2x10 -_.M to about 10—10M and the concentration of prealbumin and retinol-binding protein is sufficient to maintain the retinoid concentration from about 2x10 —5M to about 10—10M.
The growth factor has a narrow physiological range for activity since the individual, uncomplexed components may be toxic to cells. The prealbumin is ideally at a range from about 50 to about 200 -g/ml. The retinol- binding protein is ideally at a range from about 20 to aobut 40 μg/ml. The optimum ratio is equimolar amounts of each component.
In this application, the term "retinoids- includes, but is not limited to, all-trans-retinol, iso ers of vitamin A such as the cis-trans isomers, derivatives of vitamin A such as retinol esters as well as the family of retinal isomers and derivatives and the family of retinoic acid, isomer and derivatives. Specific examples include all-trans-retinol, all-trans-retinal, 13-cis-retinol and 13-cis-retinal.
In one embodiment of the invention the prealbumin in the complex may be characterized as mammalian. In another embodiment, the mammalian prealbumin may be characterized as bovine or human.
This invention also provides a complex consisting essentially of retinol-binding protein and a retinoid
which binds to retinol-binding protein, wherein the concentration of retinoid in the complex is from about
2x10 -5M to about 10—10M and the concentration of retinol-Binding protein is sufficient to maintain the rree1tinoid concentration from about 2x10 -5M to about 10
The present invention also provides a composition for enhancing the growth of human B cells in culture which comprises an amount of the complex of this invention effective to enhance i_he growth of human B cells and a nutrient medium.
The nutrient medium may be any of the standard mediums which meets the minimum biochemical requirement to sustain growth of cells. One such example includes but is not limited to a basal amino acid/salt mixture such as RPMI 1640 supplemented with insulin transferin- scleinium and essential fatty acids bound to albumin. These mediums are well known in the art.
This invention also provides a composition for enhancing the growth of human B cells in culture which comprises an amount of the complex of the subject invention effective to enhance the growth of human B cells and a nutrient medium.
This invention further provides a method of making the complex of this invention which comprises contacting retinol-binding protein with a retinoid which binds to retinol-binding protein under conditions such that the protein and the retinoid form an intermediate complex, and contacting the intermediate complex with prealbumin under conditions that the intermediate complex and the prealbumin form a complex, wherein the concentration of
retinoid in the complex is from about 2x10-5M to about
10 M and the concentration of prealbumin and retinol- binding protein is sufficient to maintain the retinoid ccoonncceennttrraattiioonn ffrroomm aabbooiut 2x10 -5M to about 10-10M, and recovering the complex.
The invention also provides a method of enhancing growth of human B cells in culture which comprises growing human B cells in a growth medium containing a concentration of the growth factor described hereinabove effective to c_..__ant-e growth of human B cells. In one embodiment of the invention, the growth medium is a synthetic growth medium. Such types of synthetic growth media include, but are not limited to, a basal medium known in the art (e.g. RPMI 1640, insulin, transferrin and essential fatty acids) supplemented with the complex of the subject invention at a concentration effective to enhance the growth of cells.
As noted before, the individual components of the growth factor, particularly the retinol, may be toxic if not contained within the complex. Moreover, the growth of human B cells will not be enhanced if the individual components of the growth factor are contacted with the B cells without first forming a complex. Therefore, the components of the growth factor, specifically the prealbumin, retinol-binding protein and retinoid, should be preassembled and complexed prior to contact with the B cells.
This invention also provides a method of enhancing growth of animal cells in culture which comprises adding to an synthetic tissue culture medium the complex of the subject invention so as to obtain in the
mediu a concentration of complex effective to enhance growth of the animal cells. In one embodiment, the cells may further be characterized as mammalian.
This invention also provides a synthetic growth medium for culturing animal cells comprising the aforementioned complex at a concentration effective to enhance cell growth. Such types of synthetic growth medium include, but are not limited to, a basal medium known in the art (e.g. RPMI 1640, insulin, transferrin and essential fatty acids) supplemented with the complex of the subject invention at a concentration effective-to enhance the growth of cells.
In one embodiment of the invention, the cells may be characterized as mammalian cells. In a further embodiment, the cells may be characterized as human B cells.
The invention also provides a method of preventing the growth of human tumor cells containing growth factor which comprises removing the growth factor from the human tumor cells.
Additionally, the invention further provides a method of preventing the growth of human tumor cells containing retinoid which comprises removing the retinoid from the human tumor cells.
In one embodiment of the invention, the retinoid is all-ttans-retinol.
The invention also provides a method of preventing the growth of human tumor cells containing a complex of retinoid ahd retinol-binding protein which comprises
substituting for the retinoid in the complex a competitive inhibitor which lacks the biological activity of the retinoid and which binds to retinol- binding protein.
In one embodiment of the invention, the retinoid is all-trans-retinol.
Finally, this invention provides a method of preventing the growth of human tumor cell containing a retinoid which comprises substituting for the retinoid a competitive inhibitor which lacks the biological activity of the retinoid.
In one embodiment of the invention the retinoid is all- trans-retinol.
This invention is illustrated in the Experimental Details section which follows. This section is set forth to aid in an understanding of the invention but is not intended to, and should not be construed to, limit in any way the invention as set forth in the claims which follow thereafter.
Experimental Defails
Methods and Materials
Retinoids. All-trans-retinol, all-trans-retinal and retinoic acid were purchased from commercially- available sources. The retinoids were dissolved at a concentration of 3 x 10 M in methanol/chloroform (3:1 v/v) with 10~4M butylated hydroxy toluene (BHT) added and stored in the dark at -20*C in a nitrogen atmosphere. Immediately before a bioassay, the str . solutions were diluted in serum-free medium.
Cells. The human EBV-transformed B LCL 5/2 was established from the peripheral blood cells of a healthy donor according to a known method (10) . The cell line was grown in RPMI 1640 supplemented with 8% fetal calf serum, L-glutamine (2 mM) , nonessential a ino acids (10 mM) , and antibiotics. The cells were tested regularly for mycoplasma infections and were consistently negative. B cells were prepared from normal human spleens by Ficoll gradient centrifugation followed by OKT4 and • 0KT8 treatment plus rabbit complement and passage through a Sephadex G-10 column. Recovered cells contained more than 90% slg+ cells. 5 x 105 cells/ml were activated either with 0.03% of fixed staphylococcus aureus Cowan stem (SAC) or 4 μg/ml of F(ab)' fragments. of rabbit anti-human i munoglobulin in serum-free medium 48 h before the beginning of the experiment.
Assay for autocrine growth activity. The assay system was a modification of the assay developed by Blazar et al. (7) and Gordon et al. (8). Lymphoblastoid cells grown for 18 to 24 hr in serum-free medium at a cell
density of 4 x 10 cells/ml or B cells activated by SAC- or anti-μ for 48 h were washed four times in RPMI 1640/0.1% fetal calf serum (FCS) . The cells (2 x 10 /ml) were then plated in a final volume of 200 μl/well of serum-free medium in 96-well microtiter plates and grown for 72 hr in the presence of log. dilutions of putative growth factor. Freshly prepared 5/2 cell line-conditioned medium was used as positive control. Fresh serum-free medium was the negative control. After 56 hr of culture the cells were labeled witii 0.4 μCi/well of [ H]thymidine (specific activity, 6.7 Ci/mmol) and 16 hr later harvested on glass fiber strips. [ H] Thymidine incorporation was measured in a liquid scintillation counter. Units of autocrine B cell growth factor (aBGF) were determined according to Table 1.
Delipidation of serum protein. LPS-free fetal bovine serum and human whole blood was purchased from commercial sources. The serum or plasma was stirred overnight at -20'C in a 100-fold volume of diethyl/ether/ethanol 1:3 (v/v). Precipitated proteins were washed twice in diethyl ether, dried, redissolved in PBS and dialyzed extensively against PBS.
Isolation of serum lipids. Human plasma or fetal bovine serum were freeze dried. All solvents had 10 —4
BHT added. The dry powder was extracted twice with chloroform/methanol 2:1 (v/v) followed by two extractions with chloroform/methanol/water 10:10:1 (v/v) . The combined extracts were dried on a rotar evaporator. Lipids were dissolved in chloroform/metha nol/water 10:10:1 (v/v) and stored at -80*C. Immediately before a bioassay, aliquots of the lipi solution were evaporated to dryness and the residua
TABLE 1
Proliferation of Dilution of RP-HPLC 5/2 Cells Fractions 23 (cp )
One unit was defined as the reciprocal of the dilution of aBGF, which shows full activity in the aBGF assay. Therefore Fraction 23 corresponds to 200 μ/ml.
The aBGF activity was determined with the assay for autocrine growth activity described in Materials and
Methods*
lipids dispersed in serum-free medium by sonication.
Lipid separation on a reversed-phase HPLC column. The crude lipid mixture was loaded on a semipreparative reversed-phase C.g HPLC column. Lipids were eluted with a linear gradient of water/methanol/chloroform. The gradient started with water/methanol 70:30 (v/v), went in 30' to 100% methanol and in another 30' to methanol/chloroform 50:50 (v/v). The flow rate was 3 ml/min.
Mass spectroscopy. Bioactive lipids were analyzed using a direct insertion probe in a V670-250 double focusing mass spectrometer.
Isolation of retinol-retinol binding protein complex. 40 mg of human prealbumin were covalently bound to 3 ml of CNBr activated sepharose. 50 ml of human plasma were passed through the column. The column was washed with 30 ml of 0.04M Tris HCl (pH 7.4)/0.5M NaCl and eluted with 1 ml fractions of distilled water. Purity was established by SDS-PAGE with silver stain and the optical densities at 280 nm and 340 nm were determined.
Assay for IL 1 activity. IL 1 activity was assessed in the lymphocyte activation factor assay (11) , which we modified slightly by using 0.5% human serum instead of FCS. Recombinant human IL 1- was used as reference standard.
Assay for tumor necrosis factor (TNF) activity. TNF activity was measured on TNF-sensitive L(M) cells (12) in 96-well microtiter plates with 1.0 μg/ml of actinomycin D added. TNF-resistant L(M) cells were used to exclude nonspecific toxicity. The cells were
3 pulsed after 24 hr with 0.4Ci/well of [ H]thymιdine for
4 hr.
Assay for IL 2 activity. IL 2 was assayed by using the IL 2-dependent murine cytotoxic T cell line 1 (13) .
Preparation of 5/2 cell line-conditioned medium. Cells were taken from their exponential phase of growth, washed once, andreseeded at 4 x 10 cells/ml in serum- free HB 101 medium. After 24 hr, conditioned medium was cleared of cells by centrifugation, passed through a 0.22-μ m filter, and used immediately for the purification of growth factor.
Ammonium sulfate precipitation. (NH.J-SO. (1683g) was added to 3 liters of 5/2 cell line-conditioned medium to achieve 80% saturation. After gentle stirring overnight at 4*C, the precipitate was spun down (10,000 x G. 30 min), dissolved in 0.05 M Tris-HCl, pH 7.8, in a final volume of 135 ml, and subsequently dialyzed against 50 volumes of 0.5 M Tris-HCl buffer, pH 7.8 for hr with five changes of the dialyzing buffer.
Anion exchange chromatography (DEAE-cellulose) . The dialyzed concentrate was loaded on 250-ml column of DEAE-cellulose, equilibrated with 0.05 M Tris-HCl, pH 7.8. Bound proteins were eluted with a stepwise gradient of Tris-buffered NaCl: 0.075 M NaCl (150 ml), 0.125 M NaCl (250 ml), 0.175 M NaCl (250 ml), and 0.300 m NaCl (250 ml). Fraction size was 25 ml. Fractions containing growth factors were pooled and concentrated by dialyzing against phosphate-buffered saline (PBS), pH .7.2, containing polyethyleneglycol (relative molecular mass (M ) 6000) (polyethyleneglycol 6000; 50% w/v).
Gel filtration. The concentration DEAE-cellulose preparation (18 ml) was applied to an AcA 54 Ultrogel column (2.6 x 90 cm), equilibrated with PBS. The flow rate was adjusted to 38 ml/hr and 7.5-ml fractions were collected. The column had been calibrated with .w. markers: bovine serum albumin (Mp 68,000), chymotrypsinogen (M 25,700), and ribonuclease A (M 14,300), all co merically obtained.
Reversed-phase high performance liquid chromatography (RP-HPLC) . The separation was performed on a C.- column. Buffer A was 100 mM CH3COONH4 pH 4.0 and buffer B was buffer A in 50% 1-propanol. The pool containing growth activity obtained from gel filtration was acidified with acetic acid to pH 4.0 and loaded onto the C. „ column without regard to sample volume. The column was washed with buffer A (20 min) , and bound proteins were eluted by using a steep gradient of 0 to 40% buffer B within the first 20 min and a 40 to 100% gradient of buffer B in 120 min. The percentage of buffer A was inversely proportional to buffer B. The flow rate was adjusted to 1 ml/min and 3-ml fractions were collected.
Isoelectric focusing (IEF) . One milliliter of purified aBGF was supplemented with 20% glycerol (v/v) and 2% ampholine (v/v) at pH 3.5.to 10. A 5 to 60% glycerol density gradient containing 2% ampholine (pH 3.5 to
100) was layered into an IEF column. The sample was applied onto the isodense region of the gradient, followed by IEF (2000 V, 24 hr, 4*C). Five-milliliter fractions were collected and. the pH was determined in each fraction. The fractions were dialyzed against HB
101 and then tested for growth activity.
-20-
NaDodSO./polyacrylamide gel electrophoresis NaDodSO,/- PAGE) . The discontinuous Tris/glycine system of Laemmli (14) was used for 1.5-mm slab gels of 15% acrylamide. The samples (lyophilized protein eluted from HPLC) were treated with 1% NaDodS04 0.0625 M Tris- HCL (pH 6.8) at 37*C for 1 hr under both reducing (5% 2-mercaptoethanol) and nonreducing conditions and then loaded on the gel. After electrophoresis, gels were stained by the silver-staining method. Apparent m.w. were ύecerlined by using protein standards: ovalbumin
(X. 43,000), chymotrypsinogen (M 'r 25,700) , β- lactoglobulin (M _r 1_8_,,4.0_0_),,, l -y_sozy Λm—e ,__r 14,300) , and cytochrome c (M 12,300). After electrophoresis under nonreducing conditions, parallel gels were sliced in 2- mm sections, and proteins from each slice were eluted into P./NaCl. The eluted material was assayed for growth-stimulatory activity.
Protein assay. The protein content of samples was measured by absorption at 280 nm. For protein concentrations of <2 μg/ml, samples were subjected to NaDodSO./PAGE; the protein bands were visualized by the silver-staining technique, and the protein concentration was estimated by comparison with a serial dilution of known amounts of proteins.
Autoradiography. Lymphoblastoid cells were labelled with 35S cysteine and 35S methionine. The supernatant was precipitated with ammonium sulfate. The prealbumin/retinol-binding protein complex was separated with an affinity column. The proteins were separated by a SDS PAGE gel with silver staining.
Results
Immune activity and homeostasis of B cells are governed by a complex network of growth and differentiational signals. Research so far has emphasized the role of proteins and glycoproteins as B cell regulators. The present inventors now have evidence that B cell- produced lipids also may participate in B cell homeostasis and that bioactive lipid molecules may use serum proteins as carriers. In attempting to study and analyze a previou l described B cell-derived B cell growth factor (10), a lipid-protein complex with novel biological properties has been found. This complex occurs in serium and in the culture fluids of EBV- transformed human B lymphocytes and of activated normal human B cells. The protein moieties of the complex are prealbumin and retinol-binding protein. The lipid moiety of the complex comprises all-trans-retinol, commonly known as vitamin A, or derivatives of vitamin A.
Human B cells transformed by Epstein-Barr virus grow in defined serum-free medium at high cell density (>100,000 cells/ml). However, when removed from high cell density serum-free conditions after one day, washed in serum-free medium and reseeded in fresh serum-free medium at low density, the growth rate decreases drastically and most of the cells die. Suitable growth conditions are restored by the additio of fetal bovine or human serum (Table 2) .
A factor released by EBV-transformed B cells, provi sionally termed "autocrine B cell growth factor" (aBGF) (10) , was purified by a four-step procedure, namel ammonium sulfate precipitation, ion exchange chro atog-
TABLE 2
Comparison of growth-stimulating effect between serum, delipidated serum proteins and serum lipids.
ΔCPM
Serum-free medium 1,952 + 138
Human serum 16,896 + 232
Delipidated serum 4,094 + 772 proteins
Serum lipid 4,360 + 266
Protein + lipid 13,211 + 721
Washed 5/2 cells (1,500/well) were incubated for 72 h in serum-free medium. DNA synthesis was assessed as described. The experiment was done in triplicate.
Protein and lipid concentrations correspond to 3% serum.
raphy, gel filtration and reversed phase HPLC. B cel stimulatory activity was monitored by an assay devise by Blazar, et al. (7). A 16 kD protein was isolate which formed dimers and tetra ers. Since its 28 N terminal amino acid sequence corresponds to the bovin prealbumin sequence at 15 of 16 residues, and sinc there is 82% homology to human prealbumin, it appear likely that the 16 kD protein constitutes the monomeri subunit of bovine prealbumin (Figure 1) . Prealbumin i a stable tetrameric serum protein consisting of fou identical subunits (11) . ^ e full physiologica functions of prealbumin are unknown, except fo evidence that it acts as a carrier for thyroxine and o vitamin A via retinal-binding protein. The subunit are so arranged as to form a central channel containin two binding sites for thyroxine (12-14) .
In the course of aBGF purification it was noted tha activity was retained through the ion-exchang chromatography, but was lost during the subsequent ge filtration step. This decrease in activity occurre despite a nearly ten-fold titrated enrichment o specific protein. The ion-exchange material yielde six-fold to ten-fold increases in H-thymidine uptak in cultures of EBV-transformed target cells, while th relative increase elicited by the gel filtratio material was merely two-fold (see Figure 2) . Thes findings prompted the current inventors to search fo a cofactor that might act in concert with the protei and which was lost during gel filtration. Back-mixin of fractions failed to restore the high proliferatio index, suggesting that the postulated cofactor wa absent from other fractions generated by ge filtration chromatography and possibly remaine absorbed to the gel-filtration matrix.
Since the protein copurifying with activity was pre¬ albumin, and prealbumin is known to function as a car¬ rier for thyroxine and vitamin A, it was envisaged that a similar molecule of small molecular weight might act as a cofactor for aBGF. Although thyroxine itself did not act in such a fashion, a cofactor was found in chloroform/methanol or ether/ethanol extracts of crude active ion-exchange chromatography fractions of aBGF, but not in elutes from the gel filtration beads. Because of its solubility in organic solvents, it was hypothesized that the costimulatory factor was a lipid. Ion exchange material extracted with an ether/ethanol mixture yielded a delipidated protein with mild stimulatory capacity (two-fold over background) , not unlike the material obtained after gel filtration. Lipid from the ether/ethanol phase showed similar low stimulatory activity, but the combination of delipidated protein and lipid restored biological activity to the high level (10-fold) obtained with the crude ion exchange fractions. Furthermore, both lipid and protein concentrations affected the level of reconstituted activity. (Figure 3). When human prealbumin was substituted for the delipidated protein, it synergized with lipid extract in a manner similar to aBGF protein (see Table 3) .
Serum lipids were 'isolated from human serum by solvent extraction with diethylether/ethanol or chlor form/methanol/water mixtures. Delipidated proteihs were the residue after ether/ethanol extraction. The growth stimulatory effects of lipids and delipidated proteins for EBV-transformed cells were tested either alone or in combination. The results of
3
Table 2 show definite, but modest increases in H-
jt
TABLE 3
Lipid (1/1,500) Without With
Washed 5/2 target cells were cultured in triplicate at
10 4 cells/ml for 72 h under conditions indicated. 3H- thymidine (0.4 μCi/well) was added for the last 16 h.
Results are recorded as the average of triplicate cultures. The standard deviations were less than 20%.
Δ c.p.m. expresses the differential between total c.p.m. and the background response (156 + 28) .
♦Microscopic inspection showed all cells to be dead.
thymidine uptake by either compound alone, but when mixed, a synergistic effect occurred which nearly matched the growth stimulation potential of whole serum.
The growth-promoting properties of the lipid extract on normal human B cells was examined. In the experiment shown in Figure 4, staphylococcus aureus (SAC) activated human B lymphoblasts gave a significant pro- liferative response to the lipid/prealbumin combination and to the crude aBGF ion exchange preparation, partic¬ ularly at lo cell density. Activated, but not resting normal B cells, also produce an equivalent lipid co¬ factor. Solvent extraction of medium conditioned by B cells stimulated with SAC (0.02%) or anti-μ (10 μg/ml) yielded a stimulatory activity indistinguishable from that derived from EBV-transformed cells.
Figure 5 shows a comparison of bioactivity between all- trans-retinol, all-trans-retinal and all-trans-retinoic acid. Bioactivity was tested on lymphoblastoid cells.
The culture medium may also be synthetic, comprising a basal Inedium known in the art (e.g. RPMI 1640, insulin, transferrin and essential fatty acids) supplemented with the complex at a concentration effective to enhance the growth of cells.
Crude lipid activity was resistant to saponification with 4M potassium hydroxide for two hours at 37*C but was not stable over prolonged periods of time in aque¬ ous solution at 4*C and was destroyed by ultraviolet light. The bioactivity decayed within hours at room temperature but decay could be slowed by the addition of the antioxidant butylated hydroxy toluene (BHT) and
by storage of the sample in the dark at -80"C in a nitrogen atmosphere. The lipid mixture was chromatographed on a reversed phase C-- HPLC column (Fig. 6) with a linear water/methanol/chloroform gradient and 89% of total bioactivity had been eluted at minute 34. Corresponding to the main bioactivity was an optical absorption peak registering at the wavelengths of 280 nm and 340 nm. The material collected in this fraction fluoresced when exposed to UV light. The low resolution mass spectrum is given in Figure 7A which shows a m/z of 286 for the molecular ion, and masses of 268, 255 and 253 respectively for the first breakdown products. A library computer search showed high homology of the observed spectrum with the reference spectrum of all-trans-retinol (Fig. 7B) . Accordingly, authentic all-trans-retinol has been tested and a growth-enhancing effect on activated human B cells has been found similar in magnitude to the ones elicited by bioactive HPLC fraction 34 and the crude serum lipid (Table 4) .
Further evidence for identity of the bioactive HPLC fraction 34 with all-trans-retinol was obtained by chromatographic comparisons which yielded identical profiles on a HPLC C-8 column and by thin layer chromatography including, in the latter method, similar bands of breakdown products.
A second group of compounds with low-titered bioactivity was observed in HPLC fractions 38 to 41, and -these were identified as retinyl esters by mass spectrometry. In addition, fractions 30 and 36 contained bioactivity. Repeat experiments with feta bovine serum gave similar compounds and bioactivities.
TABLE 4
Comparison between the growth-stimulating effect of human serum, retinol and purified lipid activity on activated human B cell blasts.
ΔCPM
SAC-blasts anti-μ blasts EBV-blasts (2,000/well) (2,000/well) (1,500/well)
515 + 53 383 + 48 1,451 + 366
3% human serum 1,780 + 230 n.d.* 10,446 + 1,021
Fraction 34 2,819 + 337 4,783 + 841 6,136 + 213 (1/5000)
Retinol _ 3,091 + 421 4,375 + 546 6,910 + 1,015 (3 x 10 M)
Washed B cell blasts were incubated for 72 h in serum-free medium. DNA synthesis was assessed as described. The experiment was done in triplicate.
*, not done.
In serum, the natural carrier of retinol is retinol binding protein (RBP) complexed with prealbumin (PA) . The trimeric complex is stable under isotonic conditions but dissociation of the two proteins occurs in distilled water. Retinol is retained by RBP. To test for the involvement of the natural carrier system, RBP was isolated by use of a solid-phase PA column consisting of human PA attached to CNBr activated Sepharose. Fresh human serum was passed through the affinity column and bound proteins were eluted with water. The eluted proteins by SDS PAGE proved to be 70% RBP, with some PA contamination and, according to their optical absorption ratio, at 280 and 340 nm of 0.7 contained retinol at approximately 80% saturation. When assayed in cultures of lymphoblastoid cells, th RBP-retinol complex showed growth-enhancing activit similar in magnitude to activities of crude seru lipids and of commercially available retinol. When th RBP-retinol complex was extracted wit methanol/chloroform and the extract subjected to HPL on a C.g column, a single activity peak emerged i fraction 34, the same fraction where authentic all trans-retinol is eluted.
As shown by autoradiography, activated human B cell produce retinol-bining protein and prealbumin an release into the medium (Figure 8) .
Dose-response curves establish that all-trans-retinol, tested in serum-free medium in the presence of RBP/PA, is optimally active at a concentration of 2 x 10" to x 10 M, a range corresponding to the physiologica concentration in serum (10~ M retinol) . A concentrations above 8 retinol is toxic to human cells in serum-free, as well as in 7% serum
supple ented medium. All-trans-retinal is comparable in bioactivity at a range of 10 —7 to 5 x 10-7 molar, but at 2 x lo" M displays toxicity. Retinoic acid, commonly--, assumed to be the most active retinol derivative in cell culture, has marginal bioactivity on
B cells at 10—5 (15 to 25% growth-enhancing capacity as compared to retinol) and is toxic at higher doses. At concentrations of 4 x 10 —6 M to 6 x 10—8 M there is a noticeable suppression of thymidine incorporation.
Mixtures of retinol and retinoic acid at appropriate concentrations are growth stimulatory. Retinoic acid has not been found in fresh serum at concentrations above 10 —8 M.
The results reported here support the contention that human B cells are. subject to control by autocrine growth factors (10) , and that this growth factor comprises prealbumin, and retinoids.
References
1. Delarco, and Todaro, G., Proc. Nat. Acad. Sci. US 75, 4001 (1978).
2. Kaighn, M.E., Kirk, D. , Szalay, M. , and Lechner J., Proc. Nat. Acad. Sci. USA 7_8, 5673 (1981).
3. Uittenbogaart, C. H., and Fahey, J.L., Proc, Nat Acad. Sci. USA 79, 7004 (1982).
4. Miller, G. , Welte, K., Holloway, K., Moore M.A.S., and Mertelsmann, R. , Leukemia: Rece Advances in Biology and Treatment, 303-312 (1985)
5. Cuttitta, F., Carney, D.N., Mulshine, J., Mood T.W. , Fedorko, J. , Fischler, A., and Minna, J.D. Nature 316. 823 (1985).
6. Welte, K., and Mertelsmann, R. , Cancer Invest. 35 (1985).
7. Blazer, B.A., Sutton, L.M., and Strome, M., Canc Res. 43, 4562 (1983) .
8. Gordon, J., Ley, S.C., Melamed, M.D., A an, P. and Hughes-Jones, N.C., J. Exp. Med. 159, 15 (1984).
9. Gordon, J., Ley, S.C., Melamed, M.D., Aman, P and Hughes-Jones, N.C., Nature 310, 145 (1984).
10. Buck, J., Hammerling, U., Hoffmann, M.K. , Lev E., and Welte, K., J. Immunol. 138, 2923-29 (1987).
11. Rask, L. , Peterson, P.A. , and Nilson, S.F. J. Biol. Chem. 246, 6087-6097 (1971).
12. Kanda, Y., Goodman, D.S., Canfield, R.E., and Morgan, F.J., J. Biol. Chem. 249, 6796-6805 (1974) .
13. Blake, C.C.F., Geisow, M.J. , and Oatley, S.J. J. Mor^ Biol. 121/ 339-356 (1978).
14. Blake, C.C.F., and Oatley, S.J. Nature 268, 115- 120 (1977).
15. Cuthbert, J.A., and Lipsky, P.E. J. Biol. Chem. « 261, 3620-3627 (1986).
16. Arai, S., Yamane, I., Tanno, Y. , and Takishima, T., Proc. Soc. Exp. Biol. Med. 159, 444-448 (1977) .
17. Svendeman, S. and Thorley-Lawson, D.A., Embo J. 6 , 1637-1642 (1987) .
Claims
What is claimed is:
l. A complex consisting essentially of prealbumin, retinol-binding protein, and a retinoid which binds to retinol-binding protein, wherein the concentration of retinoid in the complex is from about 2x10 -5M to about
10 M and the concentration of prealbumin and retinol- binding protein is sufficient to maintain the retinoid
—5 —10 concentration from about 2x10 M to about 10 M.
2. The complex of .laim 1, wherein the molar ratio of prealbumin, retinol-binding protein, and retinoid is about 1:1:1.
3. The complex of claim 1, wherein the retinoid is all-trans-retinol.
4. The complex of claim 1, wherein the retinoid is all-trans-retinal.
5. The complex of claim 1, wherein the retinoid is 13-cis-retinol.
6. The complex of claim 1, wherein the retinoid is 13-cis-retinal.
7. The complex of claim 1, wherein the prealbumin is mammal prealbumin.
8. The complex of claim 7, wherein the prealbumin is human prealbumin.
9. The complex of claim 7, wherein the prealbumin is bovine prealbumin.
10. A complex consisting essentially of retinol- binding protein and a retinoid which binds to retinol- binding protein, wherein the concentration of retinoid
—5 —10 in the complex is from about 2x10 M to about 10 M and the concentration of retinol-binding protein is sufficient to maintain the retinoid concentration from
—5 —10 about axlO 3M to about 10 M.
11. A composition for enhancing the growth of human B cells in culture which comprises an amount of the complex of claim 1 effa tive to enhance the growth of human B cells and a nutrient medium.
12. A method of preparing the complex of claim 1 which comprises contacting retinol-binding protein with a retinoid which binds to retinol-binding protein under conditions such that the protein and the retinoid form an intermediate complex, and contacting the intermediate complex with prealbumin under conditions that the intermediate complex and the prealbumin form a complex, wherein the concentration of retinoid in the complex is from about 2x10 —5M to about 10—10M and the concentration of prealbumin and retinol-binding protein is sufficient to maintain the retinoid concentration from about 2x10 —5M to about 10—10M, and recovering the complex.
13. A method of enhancing the growth of human B cells in culture which comprises culturing the human B cells in a growth medium containing an amount of the complex of claim 1 effective to enhance the growth of human B cells.
14. The method of claim 13, wherein the growth medium is a synthetic growth medium.
15. A method of enhancing growth of animal cells in culture which comprises adding the complex of claim 1 to a synthetic tissue culture medium so as to obtain in the medium a concentration of complex effective to enhance growth of the animal cells.
16. The method of claim 15, wherein the animal cells are mammalian cells.
17. A synthetic growth medium fo.v culturing animal cells comprising the complex of claim 1 at a concentration effective to enhance cell growth.
18. The synthetic growth medium of claim 17, wherein the animal cells are mammalian cells.
19. The synthetic growth medium of claim 18, wherein the mammalian cells are human B cells.
20. A method of preventing the growth of human tumor cells containing growth factor which comprises removing the growth factor from the human tumor cells.
21. A method of preventing the growth of human tumor cells containing retinoid which comprises removing the retinoid from the human tumor cells.
22. The method of claim 21, wherein the retinoid is all-trans-retinol.
23. A method of preventing the growth of human tumor cells containing a complex of retinoid and retinol- binding protein which comprises substituting for the retinoid in the complex a competitive inhibitor which lacks the biological activity of the retinoid and which binds to retinol-binding protein.
24. The method of claim 23, wherein the retinoid is all-trans-retinol.
25. A method of preventing the growth of human tumor cells containing a retinoid which comprises substituting for the retinoid a competitive inhibitor which lacks the biological activity of the retinoid.
26. The method of claim 25, wherein the retinoid is all-trans-retinol.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US38701389A | 1989-07-28 | 1989-07-28 | |
US387,013 | 1989-07-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1991001745A1 true WO1991001745A1 (en) | 1991-02-21 |
Family
ID=23528066
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1990/004198 WO1991001745A1 (en) | 1989-07-28 | 1990-07-26 | Growth factors containing vitamin a or other retinoids and uses thereof |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU6141490A (en) |
WO (1) | WO1991001745A1 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5279686A (en) * | 1991-02-20 | 1994-01-18 | Canon Kabushiki Kaisha | Solar cell and method for producing the same |
EP1807103A2 (en) * | 2004-11-04 | 2007-07-18 | Sirion Therapeutics, Inc. | Modulators of retinol-retinol binding protein (rbp)-transthyretin (ttr) complex formation |
US8314152B2 (en) | 2004-06-23 | 2012-11-20 | Acucela, Inc. | Methods and compositions for treating ophthalmic conditions with retinyl derivatives |
-
1990
- 1990-07-26 WO PCT/US1990/004198 patent/WO1991001745A1/en unknown
- 1990-07-26 AU AU61414/90A patent/AU6141490A/en not_active Abandoned
Non-Patent Citations (9)
Title |
---|
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, Volume 157, No. 3, issued 30 December 1988, MARTONE et al., "Retinal-Binding Protein is Synthesized in the Mammalian Eye", pages 1078-1084. * |
CANCER RESEARCH, Volume 43, issued October 1983, BLAZER et al., "Self-Stimulating Growth Factor Production by B-Cell Lines Derived from Burkitt's Lymphomas and other Lines Transformed in Vitro by Epstein-Barr Virus", pages 4562-4568. * |
CHEMICAL ABSTRACTS, Volume 112, issued 01 January 1990, BERNI et al., "Discussion of the Bovine Serum Retinol-Protein-Transthyretin Complex and Purification of the Two Interacting Proteins", see entire Abstract #2841e. * |
CHEMICAL ABSTRACTS, Volume 113, issued 16 July 1980, BUCK et al., "Retinol is Essential for Growth of Activated Human B Cells", see entire Abstract #22497w. * |
JOURNAL OF EXPERIMENTAL MEDICINE, Volume 159, issued May 1984, GORDON et al., "Soluble Factor Requirements for the Autostimulatory Growth of B Lymphoblasts Immortilized by Epstein-Barr Virus", pages 1554-1559. * |
THE JOURNAL OF CLINICAL INVESTIGATION, Volume 75, issued February 1985, AMBRUS et al., "Human B Lymphoma Cell Line Producing B Cell Growth Factor", pages 732-739. * |
THE JOURNAL OF IMMUNOLOGY, Volume 133, No. 6, issued December 1984, BROOKS et al., "A B Cell Growth Factor-Like Activity is Secreted by Cloned Neoplastic B Cells", pages 3133-3137. * |
THE JOURNAL OF IMMUNOLOGY, Volume 136, No. 12, issued 15 June 1986, JURGENSEN et al., "Production of B Cell Growth Factor by Normal Human B Cells", pages 4542-4547. * |
THE JOURNAL OF IMMUNOLOGY, Volume 138, No. 9, issued 01 May 1987, BUCK et al., "Purification and Biochemical Characterization of a Human Autocrine Growth Factor Produced by Epstein-Barr Virus-Transformed B Cells", pages 2923-2928. * |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5279686A (en) * | 1991-02-20 | 1994-01-18 | Canon Kabushiki Kaisha | Solar cell and method for producing the same |
US8314152B2 (en) | 2004-06-23 | 2012-11-20 | Acucela, Inc. | Methods and compositions for treating ophthalmic conditions with retinyl derivatives |
US8410168B2 (en) | 2004-06-23 | 2013-04-02 | Acucela, Inc. | Methods and compositions for treating ophthalmic conditions with retinyl derivatives |
EP1807103A2 (en) * | 2004-11-04 | 2007-07-18 | Sirion Therapeutics, Inc. | Modulators of retinol-retinol binding protein (rbp)-transthyretin (ttr) complex formation |
EP1807103A4 (en) * | 2004-11-04 | 2009-02-11 | Sirion Therapeutics Inc | Modulators of retinol-retinol binding protein (rbp)-transthyretin (ttr) complex formation |
Also Published As
Publication number | Publication date |
---|---|
AU6141490A (en) | 1991-03-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Buck et al. | Retinol is essential for growth of activated human B cells. | |
Massague | Epidermal growth factor-like transforming growth factor. I. Isolation, chemical characterization, and potentiation by other transforming factors from feline sarcoma virus-transformed rat cells. | |
Zasloff et al. | Antimicrobial activity of synthetic magainin peptides and several analogues. | |
Rouzer et al. | Dynamics of leukotriene C production by macrophages. | |
Russell et al. | Partial characterization of a hepatocyte growth factor from rat platelets | |
Matrisian et al. | Further purification of epidermal growth factor by high-performance liquid chromatography | |
Lockhart et al. | The amino acid sequence in bacitracin A | |
Hirschberger et al. | Determination of cysteinesulfinate, hypotaurine and taurine in physiological samples by reversed-phase high-performance liquid chromatography | |
Ingbar et al. | Observations concerning the heterogeneity of ovine thyroglobulin | |
JPS58190397A (en) | Interrykin 2 and purification thereof | |
Bloj et al. | Isolation and amino acid analysis of a nonspecific phospholipid transfer protein from rat liver | |
EP0132125B1 (en) | A protein having antitumor activity | |
Roos et al. | Isolation of five active thyrotropin components from human pituitary gland | |
NZ211525A (en) | Immunosuppressant factor from human glioblastoma cells | |
WO1991001745A1 (en) | Growth factors containing vitamin a or other retinoids and uses thereof | |
US5518914A (en) | Growth medium containing a complex of prealbumin, a retinoid and retinol-binding protein used to enhance B cell growth | |
Feldman et al. | Purification of a membrane-derived human erythroid growth factor. | |
Trivers et al. | Mouse lymphotoxin | |
Chang et al. | Cellular immunity of mice to Leishmania donovani in vitro: lymphokine-mediated killing of intracellular parasites in macrophages. | |
VINCENT et al. | Purification of HLA antigens from urine | |
KR100361894B1 (en) | Substituted Chromatography Methods and Purified Hemoglobin Products | |
EP0132359A2 (en) | Natural human interleukin-2 and production thereof | |
Siddiqui et al. | Free amino-acids of blood plasma and erythrocytes of normal ducks and ducks infected with malarial parasite, plasmodium lophurae | |
Gordon et al. | Inositol is a required nutrient for keratinocyte growth | |
Kano‐Sueoka et al. | Growth stimulating activity in bovine pituitary extract specific for a rat mammary carcinoma cell line |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU CA JP |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB IT LU NL SE |
|
NENP | Non-entry into the national phase |
Ref country code: CA |